Introduction {#sec1}
============

Outbreaks caused by multidrug resistant *Acinetobacter baumannii* strains have been intensively documented worldwide ([@bib1]). With the increasing number of carbapenem-resistant *A. baumannii*, outbreaks of *A. baumannii* were expanding. One data showed that resistance to carbapenem increased from 1.0% in 2003 to 58.0% in 2008 in Detroit Medical Center health system ([@bib2]). In China, *A. baumannii* has recently become an important pathogen causing the nosocomial infection in hospitals. The infection rate of *A. baumannii* is always in the top three in total clinical isolates of Gram-negative bacilli, second only to *Escherichia coli* and *Klebsiella pneumoniae*. In 2014, *A. baumannii* isolated from nonfermenting Gram-negative bacilli was always in the first place in clinical tests ([@bib4]; [@bib3]; [@bib3]).

The analysis results of multilocus sequence typing (MLST) demonstrated that multiple STs were prevalent in the outbreak regions. Ying reported that ST208 was the most prevalent, followed by ST191 and ST729 in the 398 isolates collected in seven regions of South China in 2012 (Ying et al. 2015). Through the whole genome sequencing, it was found that *bla*~OXA-23~-producing *A. baumannii* ST208 strains emerged and rapidly spread in Hangzhou First People's Hospital ([@bib6]). Just recently, [@bib7] reported that sequence type (ST) 191 was the predominant clone, followed by the ST208 and ST369 in the hospital in Korea.

At present, *A. baumannii* strains were mainly isolated from the clinical specimens, as blood, urine, tissues, and sputum ([@bib8]; [@bib12]; [@bib10]; [@bib11]; [@bib6]). In our laboratory, we have been focused on the epidemiology of *A. baumannii* isolates from sputum ([@bib13]; [@bib14]). However, some reports have shown that *A. baumannii* can survive and transmit in the air ([@bib15]; [@bib16]). To date, the homology relationship between the airborne *A. baumannii* isolates from hospital air and those isolated from patients has not been extensively studied. In this study, twenty-five isolates of non-duplicate *A. baumannii* were obtained from patients and the air of wards' corridors during May -- Jun. and Oct. -- Nov. of 2014. The molecular epidemiological characterization of the isolated *A. baumannii*, such as drug resistance, and types of resistance genes, was compared to understand the relationship between the airborne *A. baumannii* and those isolated from patients.

Experimental {#sec2}
============

Materials and Methods {#sec3}
---------------------

**Ethical approval.** Samples of patients were acquired during a routine checkup by medical staffs. The study was approved by the Ethics Committee of Tai'an City Central Hospital and carried out in accordance with the approved guidelines.

**Source of the isolates.** From May 12 to Jun. 5 and Oct. 11 to Nov. 15, 2014, *A. baumannii* isolates were obtained from patients hospitalized in four different wards, including the intensive care unit (ICU), emergency intensive care unit (EICU), respiratory intensive care unit (RICU) and geriatrics ward (GW). Meanwhile, airborne *A. baumannii* isolates were obtained from the air of the wards and adjacent corridors using the Andersen 6-stage air sampler. Each stage of the sampler has a plate with 400 holes of uniform diameter, according to the method described in previous studies ([@bib17]; [@bib16]). In brief, the sampler was placed in the center of wards and corridors (closed) at a height of 1.5 m above the ground. Airborne *A. baumannii* was collected at a calibrated flow rate of 28.3 l/min for 20 min, and MacConkey agar (Oxoid, Basingstoke, England) was used as the sampling medium. At each sampling site, four duplicate air samples were collected once per week. The number of colonies was about 30--300 in each stage. Temperature and relative humidity were recorded throughout the sampling periods (temperature 20--25°C; relative humidity 73--83%).

**Bacterial identification and drug susceptibility test.** Bacterial identification was performed by using an VITEK-2 bacterial instrument (BioMerieux, Lyons, France) following the operation instruction. Drug susceptibility test was performed by two different methods: the sensitivity of tigecycline and polymyxin B was detected by the Etest method (AB Biodisk, Solna, Sweden); the sensitivity of the remaining fourteen antibiotics was detected using the minimal inhibitory concentration method. The susceptibility testing result of tigecycline was explained according to Food and Drug Administration (FDA) guideline (http://www.fda.org.uk/sitemap.aspx). The criteria of the susceptibility of other agents were adapted from the Clinical and Laboratory Standards Institute (CLSI) (http://clsi.org/standards/). The criteria of multidrug resistant (MDR) *A. baumannii*, extensively drug-resistant (XDR) *A. baumannii* and pandrug-resistant (PDR) *A. baumannii* were referred to the previously described ([@bib18]).

**Pulsed field gel electrophoresis (PFGE).** Clonal relatedness of 25 *A. baumannii* strains isolated in this study was determined by PFGE ([@bib19]). Briefly, the bacterial chromosomal DNA was digested with 60 U of *ApaI* (Takara, Dalian, China) in a 37°C. *Salmonella* serotype Braenderup strain (H9812) was digested with *XbaI* (Takara, Dalian, China) and used as the molecular weight standard, the DNA fragments were separated on agarose gel using a clamped homogeneous electric field electrophoresis-Mapper XA system (Bio-Rad, California, USA). The PFGE images were analyzed using the Gel Doc software (Bio-Rad, California, USA) and the genetic relatedness of the *A. baumannii* isolates were evaluated using the BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium). The cutoff level of 85% was set to define clonal clustering of the PFGE types.

**Multilocus sequence typing (MLST).** The sequence types (STs) of *A. baumannii* strains were determined by MLST using the previously described method ([@bib20]). In brief, the internal fragments of seven housekeeping genes, including citrate synthase (gltA), DNA gyrase subunit B (gyrB), glucose dehydrogenase B (gdhB), homologous recombination factor (recA), 60-kDa chaperonin (cpn60), glucose-6-phosphate isomerase (gpi) and RNA polymerase σ70 factor (rpoD) were amplified by PCR. The positive sequences were further analyzed using the *A. baumannii* PubMLST database (http://pubmlst.org/abaumannii).

###### 

Susceptibility profiles of 20 clinical *A. baumannii* isolates.

![](pjm-67-3-333-t001)

  Antibiotics                     Susceptible   Resistant        
  ------------------------------- ------------- ----------- ---- -------
  Amikacin                        3             15.0%       17   85.0%
  Ceftazidime                     0             0.0%        20   100%
  Ciprofloxacin                   0             0.0%        20   100%
  Levofloxacin                    0             0.0%        20   100%
  Gentamicin                      0             0.0%        20   100%
  Tobramycin                      3             15.0%       17   85.0%
  Ceftriaxone                     0             0.0%        20   100%
  Cefotaxime                      0             0.0%        20   100%
  Cefepime                        0             0.0%        20   100%
  Imipenem                        0             0.0%        20   100%
  Meropenem                       0             0.0%        20   100%
  Trimethoprim/sulfamethoxazole   6             30.0%       14   100%
  Piperacillin/tazobactam         0             0.0%        20   100%
  Tigecycline                     20            100%        0    0.0%
  Polymyxin B                     20            100%        0    0.0%

###### 

Susceptibility profiles of the airborne and clinical strains with the highest similarity.

![](pjm-67-3-333-t002)

  Strain / Antibiotics            TAaba004   TAaba012
  ------------------------------- ---------- ----------
  Amikacin                        R          R
  Ceftazidime                     R          R
  Ciprofloxacin                   R          R
  Levofloxacin                    R          R
  Gentamicin                      R          R
  Tobramycin                      R          R
  Ceftriaxone                     R          R
  cefotaxime                      R          R
  Cefepime                        R          R
  Imipenem                        R          R
  Meropenem                       R          R
  Trimethoprim/sulfamethoxazole   R          R
  Piperacillin/tazobactam         R          R
  Tigecycline                     S          S
  Polymyxin B                     S          S

Note: "R" indicates resistant, "S" indicates susceptible.

**Drug resistance genes.** Bacterial DNA were extracted and the carbapenemase genes, including *bla*~OXA-23-like~, *bla*~OXA-24-like~, *bla*~OXA-48~, *bla*~OXA-50~, *bla*~OXA-51-like~, *bla*~OXA-55~, *bla*~OXA-58-like~, *bla*~OXA-60~, and *bla*~OXA-64~, the 16S rRNA methylase genes *armA* and *rmtB* were amplified by PCR as previously described ([@bib21]; [@bib22]). The positive bands were sequenced and then compared to the Genbank database ([@bib14]).

Results {#sec4}
=======

**Isolation of *A. baumannii* strains.** Twenty *A. baumannii* clinical strains were isolated from 356 patients and five strains were isolated from 4 out of 64 air samples in duplicate during this experimental period (8 weeks). Wherein two *A. baumannii* strains (TAaba015 and TAaba014) were isolated from the same air sample from ICU corridor in 08.11.2014.

**Drug susceptibility patterns.** A total of twenty-five non-duplicate *A. baumannii* isolates were obtained, including twenty from the clinical samples and five from the adjacent corridors of the wards. Fifteen commonly used antibiotics (amikacin, ceftazidime, ciprofloxacin, levofloxacin, gentamicin, tobramycin, ceftriaxone, cefotaxime, cefepime, imipenem, meropenem, trimethoprim/sulfamethoxazole, piperacillin/tazobactam, tigecycline, and polymyxin B) were selected for drug susceptibility test. The result showed that only one out of the five airborne isolates (TAaba013) was non-MDR *A. baumannii*, which was only resistant to ceftazidime, ceftriaxone, cefotaxime, and cefepime. All twenty clinical isolates were MDR *A. baumannii*, and susceptible to tigecycline and polymyxin B.

**Drug resistance genes.** All isolates had the *bla*~OXA-51-like~ resistant gene, and twenty-four had the *bla*~OXA-23-like~ gene except one airborne isolate (TAaba014). However, other seven resistance genes of carbapenemases were not detected in this study. These results indicated that *bla*~OXA-23-like~ gene was responsible for the carbapenemase resistance. In addition, twenty isolates carried the 16S rRNA methylase gene *armA*. No *rmtB* gene was detected in all isolates.

**PFGE and MLST.** As shown in Fig. [1](#fig1){ref-type="fig"}, the isolates can be clustered into eight PFGE types (A-H) and four STs (ST208, ST369, ST195 and ST530). One airborne isolate (TAaba012) had the same PFGE and ST types as one clinical isolates (TAaba004). They were isolated from the same ward (EICU) during the same period (May -- Jun 2014). Similarly, in another ward (intensive care unit, ICU), one airborne isolate (TAaba008) was found to be closely related to three clinical isolates (TAaba002, TAaba009, and TAaba011) in terms of PFGE and ST types (type D and ST208, respectively).

![Dendrogram showing the PFGE and MLST profiles of the *A. baumannii* isolates. The dendogram was generated by the BioNumerics software. The sampling date, isolate number, ward and source, PFGE and ST types and resistance genes are shown for each isolate.](pjm-67-3-333-g001){#fig1}

In the second sampling period (Oct. 11 to Nov. 15, 2014), we collected three non-reduplicate airborne isolates (TAaba013, TAaba014 and TAaba015). We did not find any clinical isolates with the same PFGE and ST types. In particular, the PFGE and ST types of TAaba013 were different from any isolates obtained in this study.

Discussion {#sec5}
==========

*A. baumannii* is a predominant cause of nosocomial infections, and the organism has been detected in water, soil, and on the surface of human body. A recent study has shown that some *A. baumannii* environmental isolates are able to survive in tap, normal saline, and distilled water with a wide range of pH and temperature for a long period of time ([@bib23]). It makes it harder for the prevention of *A. baumannii* spread in a nosocomial environment. *A. baumannii* is often transmitted through physical objects, like stethoscopes, computers, milk pumps, and headboards of beds. In this study, we investigated the genetic relationship of the *A. baumannii* isolates from the air and patients, and the possible transmission pathway through the air.

Our results show that one airborne *A. baumannii* (TAaba012) isolated in the EICU and one clinical isolate (TAaba004) isolated in the same ward shares 100% similarity in PFGE and MLST, indicating *A. baumannii* might be transmitted through air. Another airborne isolate (TAaba008) obtained in ICU was also found to be the same strain as three clinical isolates (TAaba002, TAaba009, and TAaba011). Based on the genetic relationship of the airborne and clinical isolates, we speculate that there could exist an air-mediated spread of this *A. baumannii* strain. Moreover, many studies demonstrated that airborne *A. baumannii* could be detected in ICU and airborne transmission of *A. baumannii* was possible ([@bib25]; [@bib24]; [@bib26]).

A total of twenty clinical isolates were obtained during the sampling period of this study, but only one isolate was found in the air, indicating airborne transmission might be affected by many factors, such as length of hospital stay, humidity, temperature, etc. Since our dataset are relatively small, we cannot draw any exclusive conclusion. Moreover, because horizontal gene transfer that can jeopardize clonal strains, PFGE is no longer the most effective technique for *A. baumannii* typing ([@bib27]), and our data can only confirm that the same strain was isolated from air and the specimens from patients, which could suggest an alternative route of transmission through air. More systematic studies with a longer period of sampling should be constructed to better understand the airborne pathway.

Treatment of *A. baumannii* infections is particularly difficult because of the resistance to a broad range of antibiotics, especially with the increasing of resistant to carbapenems ([@bib28]). Although mechanisms of resistance to carbapenems were very complex, resistance genes play an important role in this process. It has been reported that *bla*~OXA-23-like~-producing *A. baumannii* were found worldwide ([@bib29]; [@bib31]; [@bib30]). In this study, the analysis showed that all strains had *bla*~OXA-51-like~ gene, one intrinsic gene in *A. baumannii*. Moreover, 96% strains (24/25) carried the *bla*~OXA-23-like~ gene, except TAaba014. These results indicated that both genes were mainly responsible for the carbapenems resistance in this area, especially the *bla*~OXA-23like~ gene and it was generally believed that *bla*~OXA-23-like~ gene was responsible for carbapenem resistance in China (Ruan et al. 2010; [@bib32]). Additionally, it has been reported that 16S rRNA methylase gene *armA* was closely related to the aminoglycosides resistance ([@bib34]), and 80% (20/25) strains had the 16S rRNA methylase gene *armA*. All of the strains showed the resistance to amikacin, tobramycin and gentamicin. Antibiotic resistance is a serious global public problem.

Taken together, in this study, we isolated twenty clinical *A. baumannii* from patients and five airborne *A. baumannii* from the ward environment. Out of the five airborne *A. baumannii*, one was found to have the same PFGE and ST type with one strain isolated from patients, indicating that the air may be an important and potential transmission way for *A. baumannii*. Considering the seriousness of nosocomial infections of *A. baumannii*, prophylactic strategies in controlling the air transmission of *A. baumannii* should be considered when new measures are designed for controlling nosocomial infections.
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